Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib for Severe COVID-19 Pneumonia
NCT05688839Phase 2Not yet recruiting
- Sponsor
- Zelgen
- Start
- Apr 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in COVID-19 pneumonia comparing Jaktinib 100mg BID with Placebo (2 arms). Primary endpoint: Efficacy of Jaktinib at 28 days. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
jaktinib
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT05688839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05688839.